Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    A non-randomized, open label, multi-center Phase II study evaluating the efficacy and safety of regorafenib
Show Display Options
Rank Status Study
1 Active, not recruiting
Has Results
Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Condition: Gastrointestinal Stromal Tumor
Intervention: Drug: regorafenib

Indicates status has not been verified in more than two years